DRUG SAFETY INFORMATION

At Lisko Pharma, we strive to ensure the highest level of quality, safety, and efficacy of our products to deliver consistent and intended results to our customers. Through robust monitoring systems and quality assurance, we produce safe healthcare products through our state-of-the-art, automated machinery, and qualified personnel.

• Lisko Pharma’s pharmacovigilance program is responsible for the collection, detection, assessment, monitoring, and prevention of side effects/adverse effects that may have been caused by its marketed products.
• We are committed to identifying and managing human safety information to help safeguard those who take our products. All employees and complementary workers of Lisko Pakistan are trained on their responsibilities to report human safety information.
• Lisko Pakistan is committed to continuously evaluating the benefit/risk profile of our products. All products in development are assessed for their benefits vs. risks at milestone reviews. Marketed products are regularly assessed throughout their lifecycles. We are committed to transparency in our evaluation and communication of these benefits and risks with patients, prescribers, payers, and regulators.
• We at Lisko Pharma strongly believe that timely reporting of all safety information linked to our medicinal products plays a vital role in the safer use of our medicines.